AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie ozurdex (dexamethasone intravitreal implant) — Worldwide reported growth YoY (%) (%)
Form 8-K Key Product Revenues Schedule
Latest, Q4 2025
6.9%
Period ended Dec 31, 2025
Change on a year earlier
+5.8 pts
1.1% in Q4 2024
History
12 quarters
Since Q1 2023
Sources
12
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie Ozurdex (dexamethasone intravitreal implant) — Worldwide reported growth YoY (%) (%), quarterly Q1 2023–Q4 2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ozurdex_ww_rep_yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.